Showing results (141-150 of 185) with videos related to
Sort By:
Pageof 19
European Journal of Haematology|September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsPaul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.Bone Marrow Transplantation|January 31, 2024
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMTMeral Beksac, Diderik-Jan Eikema, Linda Koster, et al.Bone Marrow Transplantation|January 21, 2023
Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMTAnna Waszczuk-Gajda, Luuk Gras, Liesbeth C de Wreede, et al.Blood|October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasoneLuca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.Bone Marrow Transplantation|May 12, 2021
Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working PartyPatrick J Hayden, Dirk-Jan Eikema, Liesbeth C de Wreede, et al.Blood Cancer Journal|September 5, 2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 studyMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.The Lancet. Oncology|June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma NetworkHeinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.Blood Advances|June 3, 2026
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUSSonja Zweegman, Thierry Facon, Vania Hungria, et al.Clinical Lymphoma, Myeloma & Leukemia|July 22, 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional StudyMohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, et al.Pageof 19